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O B J E C T I V E S We investigated the prevalence and clinical risk factors of carotid vessel wall
inﬂammation by means of 18F-ﬂuorodeoxyglucose positron emission tomography (FDG-PET) in a
population consisting of coronary artery disease (CAD) patients.
B A C KG ROUND The atherosclerotic disease process is characterized by inﬁltration and retention of
oxidized lipids in the artery wall, triggering a disproportionate inﬂammatory response. Efforts have been made to
use noninvasive imaging to quantify this inﬂammatory response in the vessel wall. Recently, carotid FDG-PET has
been shown to reﬂect the metabolic rate of glucose, a process known to be enhanced in inﬂamed tissue.
METHOD S Carotid inﬂammation was quantiﬁed in 82 CAD patients (age 62  10 years) as the
maximum target-to-background ratio (wholevesselTBRmax). Furthermore, we assessed the maximal stan-
dardized uptake value values (wholevesselSUVmax), the single hottest segment (SHS), and the percent
active segments (PAS) of the FDG uptake in the artery wall, measured by FDG-PET.
R E S U L T S Whole-vessel TBRmax 1.8 was present in 67%, 2.0 in 39%, 2.2 in 23%, and 2.4 in
12% of the population. Multiple linear regression analysis with backward elimination revealed that body
mass index (BMI) 30 kg/m2 (p  0.0001), age 65 years (p  0.01), smoking (p  0.02), and
hypertension (p  0.01) were associated with wholevesselTBRmax. The number of components of the
metabolic syndrome was also associated with wholevesselTBRmax (p  0.02). In similar analyses,
wholevesselSUVmax was associated with BMI 30 kg/m
2 (p  0.0001), age 65 years (p  0.004), male
gender (p  0.02), and hypertension (p  0.04); SHS with BMI 30 kg/m2 (p  0.0001), age 65 years
(p  0.02), smoking (p  0.04), and hypertension (p  0.05); PAS with BMI 30 kg/m2 (p  0.001),
smoking (p  0.03), and hypertension (p  0.01).
CONC L U S I O N S Carotid inﬂammation as revealed by FDG-PET is highly prevalent in the CAD population
and is associated with obesity, age over 65 years, history of hypertension, smoking, and male gender. Artery wall
FDG uptake increased when components of the metabolic syndrome clustered. (J Am Coll Cardiol Img 2011;4:
1195–205) © 2011 by the American College of Cardiology Foundation
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1196T
he atherosclerotic disease process is character-
ized by infiltration and retention of oxidized
lipids in the artery wall, triggering a dispropor-
tionate inflammatory response (1). Preventive
trategies have focused on controlling risk factors, such
s smoking, blood pressure, and serum lipid levels,
hich have had partial success in reducing the inci-
ence of atherothrombotic events (2). Nonetheless,
ubstantial residual risk remains, even when treatment
oals are fully met (3).
Increasing interest has now turned to the inflam-
atory component of atherogenesis. Serum biomark-
rs of inflammation have emerged as independent
redictors of coronary artery disease (CAD). In fact, a
ecent study in 1,117 stable CAD patients showed
hat subjects with both C-reactive protein (CRP) and
yeloperoxidase in the highest tertile had a 5.3-fold
increased risk of cardiovascular mortality
compared with patients in the lowest tertiles
(4). Moreover, the JUPITER (Justification
for the Use of Statins in Primary Prevention:
An Intervention Trial Evaluating Rosuvas-
tatin) trial showed that identifying patients
at risk by using CRP and treating them
accordingly with statins can reduce cardio-
vascular event rates by 57% compared with
placebo (5). Currently, novel pharmacother-
apies that target anti-inflammatory path-
ways in atherosclerosis are being investigated
(6).
In line with this development, efforts
have been made to use noninvasive imag-
ing to quantify vessel wall inflammation.
Recently, carotid 18F-fluorodeoxyglucose
positron emission tomography (FDG-
PET) has been shown to reflect the met-
abolic rate of glucose, a process known to be
enhanced in inflamed tissue. In fact, FDG uptake is
significantly associated with both the degree of
macrophage infiltration and the levels of inflamma-
tory gene expression in plaques (7–9). Furthermore,
this noninvasive technique is capable of assessing
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To further validate whether carotid FDG-PET is
a surrogate marker for vessel wall inflammation, it is
important to investigate the relation between
FDG-PET and CAD risk factors. A previous study
showed that carotid inflammation was associated
with several CAD risk factors (12). However, this
retrospective study was limited by the fact that it
only included cancer patients with a low prevalence
of CAD. In a more recent study by Rudd et al. (13),
involving 41 patients with vascular disease or mul-
tiple cardiovascular risk factors, there was signifi-
cantly higher carotid FDG uptake in patients with
documented CAD and in males (compared with
females). A limitation of that study was the heter-
ogeneity of the study population with respect to
their cardiovascular disease burden as well as the
small number of patients. Therefore, the prevalence
of vessel wall inflammation and its relationship with
CAD risk factors in a predefined CAD population
is still not fully understood.
The aim of the current study was to assess the
prevalence of carotid vessel wall inflammation as
assessed by FDG-PET and to identify which clin-
ical risk factors are associated with carotid inflam-
mation in a population consisting of patients with
documented CAD.
M E T H O D S
Study design. This was a cross-sectional study, in-
vestigating the prevalence of carotid vessel wall
inflammation and the relation between clinical risk
factors and carotid inflammation as assessed by
FDG-PET. The study was conducted at the Mount
Sinai School of Medicine, New York. The study
protocol was reviewed and approved by the institu-
tional review board, and all subjects gave written
informed consent. Inclusion criteria were males and
females with a diagnosis of CAD. CAD was defined
as a history of myocardial infarction, percutaneous
r Cardiovascular Institute and Marie-Josée and
edicine, New York, New York; ¶Division of
om; #Division of Nuclear Medicine, Department
k; **The Centro Nacional de Investigaciones
g Clinical Trials Unit, Mount Sinai School of
IHR Cambridge Biomedical Research Centre
Blood Institute grant R01 HL071021 (Z.A.F.).
ical Systems and Lantheus Medical Imaging. All
ents of this paper to disclose. H. William Strauss,eine
of M
ingd
Yor
agin
he N
and
ed
contB B R E V I A T I O N S
N D A C R O N YM S
BMI bodymass index
CAD coronary artery disea
CT computed tomograph
FDG-PET 18F-
fluorodeoxyglucose positron
emission tomography
HDL high-density lipopro
cholesterol
PAS percent active segme
ROI region of interest
SHS single hottest segme
SUV standardized uptake
value
TBR target-to-background
t
w
p
p

a
W
m
o
(
a
P
a
(
P
i
r
s
(
p
r
t
h
b
i
q
d
t
M
r
i
a
r
a
g
c
o
o
a
a
b
t
p
w
c
m
t
b
i
v
u
a
c
t
F
f
fi
e
t
m
(
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 1 1 , 2 0 1 1
N O V E M B E R 2 0 1 1 : 1 1 9 5 – 2 0 5
Bucerius et al.
Carotid Vessel Wall Inflammation in CAD Patients
1197transluminal coronary intervention or coronary ar-
tery bypass surgery. Subjects with previous carotid
surgery or fasting glucose levels 11.1 mmol/l were
excluded (14).
Questionnaire, and biometric and biochemical
measurements. Presence of cardiovascular risk fac-
ors, use of medication, and family history of CAD
ere assessed by a questionnaire. Presence of hy-
ertension was defined as a history systolic blood
ressure140 mm Hg, or a diastolic blood pressure
90 mm Hg. Diabetes was defined as use of an
ntidiabetic treatment (diet, oral, parenteral).
eight and height were measured to calculate body
ass index (BMI). Fasting glucose levels were
btained by fingerstick blood glucose measurements
Accu-Chek Advantage, Roche Diagnostics, Indi-
napolis, Indiana) prior to FDG administration.
FDG-PET/computed tomography imaging. FDG-
ET/computed tomography (CT) was performed
fter an overnight fast using a GE Healthcare
Milwaukee, Wisconsin) LightSpeed Discovery ST
ET/CT scanner (14,15). FDG was administered
ntravenously (562.4  81.4 MBq), and patients
ested comfortably for 99 to 193 min before the
can of the neck was started. A low-dose CT scan
140 kV, 80 mA, and 4.25-mm slice thickness) was
erformed for attenuation correction and co-
egistration. No CT contrast agent was adminis-
ered. Head and neck were placed into a head
older for imaging of the carotids. Images from 1
ed position (15.5 cm) with coverage extending
nferior to the internal auditory meatus were ac-
uired in 3-dimensional mode for 15 min.
Image analysis. Image analysis was performed on a
edicated, commercially available workstation (Ex-
ended Brilliance Workspace V4.0.0.3206, Philips
edical Systems Inc., Cleveland, Ohio). An expe-
ienced reader (J.B.) analyzed all scans. To assess
ntraobserver agreement, a subset of 15 randomly
ssigned scans were analyzed twice by the same
eader, with a minimum of 14 days between the first
nd second reading to avoid recall bias.
After loading the PET and CT images, the
eneral imaging quality was reviewed, and as appli-
able, the following parameters were also reviewed:
ptimal counts, coverage, and image reconstruction
f both carotids, and co-registration of the PET
nd CT images. Data were excluded from the
nalysis if significant motion artifact, as assessed by
lurring edges of the CT and/or movement be-
ween the PET and CT co-registered images was
resent. In general, each slice of the fused PET/CT
as judged as 1 segment of the carotids. Thearotid artery was divided anatomically into com-
on, internal, and external carotid arteries, respec-
ively. Only the common carotid artery up to the
ifurcation was analyzed on both sides of the neck
n order to ensure a correct identification of the
essel anatomy and to minimize the impact of FDG
ptake in surrounding structures. Slices where the
natomy of the artery could not be identified with
ertainty or those slices with a high FDG uptake in
he surrounding tissue/structures (affecting the
DG uptake within the vessel) were excluded from
urther analysis. Arterial FDG uptake was quanti-
ed by drawing a region of interest (ROI) around
ach artery on every slice of the co-registered
ransaxial PET/CT images (Fig. 1). Next, the
aximal arterial standardized uptake value
SUVmax) was calculated as the maximal pixel
activity within the ROI of every slice of the vessel.
The SUV is the decay-corrected tissue concentra-
tion of FDG in kilobecquerels per milliliter, ad-
justed for the injected FDG dose and the body
weight of the patient, and is a well-recognized
method for quantification of FDG-PET data (16).
By averaging the maximum SUV values of all
arterial slices of the left and right carotid arteries, a
wholevesselSUVmax value was derived for the carotid
arteries. The maximal arterial target-to-background
ratio (TBRmax) was then calculated by correcting
Figure 1. FDG-PET Image Analysis
This ﬁgure shows 1 slice of the fused positron emission tomograph
raphy (PET/CT) images of the neck in transaxial view. Regions of in
drawn around the outer border of the vessel walls of the left and r
arteries, as well as, for evaluation of the 18F-ﬂuorodeoxyglucose (F
ity, within the lumen of both jugular veins (SUVmax, SUVmean, and dy/computed tomog-
terest (ROIs) (yellow)
ight common carotid
DG) blood pool activ-
iameter of the ROIs).SUV  standardized uptake value.
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1198the SUVmax for blood activity. This was done by
ividing the SUVmax values in the artery by the
verage blood SUVmean, estimated from both jug-
lar veins to produce a blood-corrected artery SUV.
his is considered to be a reflection of arterial FDG
ptake (17). For evaluation of the mean FDG blood
ool uptake, as depicted by the mean SUVmean, at
east six 3- to 4-mm ROIs were placed in consec-
tive slices of both jugular veins and averaged.
orrected SUVmax values were than averaged in
order to derive a wholevesselTBRmax for both carotid
rteries. Additionally, we identified the single hot-
est segment (SHS), defined as the highest TBRmax
value of the carotid arteries, as well as the percent
active segments (PAS) of each common carotid
artery. PAS reflects the percentage of all segments
of ether the left or right carotid artery above a
pre-defined threshold, namely TBRmax 1.9. This
threshold was determined by calculating the median
of all wholevesselTBRmax values (TBRmax1.9) of the
ncluded patients.
In order to provide information about the prev-
lence of different degrees of FDG uptake in both
ommon carotid arteries, we defined 4 different
otential cutoff values for vessel wall inflammation,
amely wholevesselTBRmax 1.8, 2.0, 2.2, and
2.4 based on the results of a previously published
study by Tawakol et al. (7).
Statistical analysis. All continuous variables are ex-
pressed as mean  SD, and categorical data as
absolute numbers and percentages throughout this
paper.
Multiple linear regression analysis with backward
elimination was used to assess the association be-
tween CAD risk factors and wholevesselTBRmax,
wholevesselSUVmax, SHS, and PAS. Whole-vessel
BRmax, wholevesselSUVmax, SHS, and PAS were the
esponse variables, and CAD risk factors the ex-
lanatory variables. The explanatory variables in-
luded were age 65 years, male gender, BMI 30
g/m2, smoking, hypertension, alcohol use, exercis-
ing, diabetes, fasting glucose levels, and family
history of cardiovascular disease. Variables were
retained if p  0.10. Multiple linear regression
nalyses were also performed to assess the associa-
ion between each of these retained individual
AD risk factors and wholevesselTBRmax, wholevessel-
SUVmax, and SHS, as well as PAS. The wholevesselT-
Rmax, wholevesselSUVmax, SHS, and PAS were
aken as the response variables, and each of the
forementioned CAD risk factors as the explana-
ory variable, adjusting for the other risk factors
BMI 30 kg/m2, age 65 years, hypertension,smoking, male gender) as potential confounders.
To assess the relation between the number of
components of the metabolic syndrome and
wholevesselTBRmax, a 1-way analysis of variance was
performed to test for between-group differences. To
assess the intraobserver agreement of the image
analysis, intraclass correlation coefficients with 95%
confidence intervals were calculated in a subgroup
of patients who underwent vascular FDG-PET
imaging at our institution (18). Depending on
normal distribution, the Pearson or Spearman rho
correlation coefficients (r) were calculated to assess
the relation between FDG circulation time (i.e., the
time interval between FDG injection and starting
time of the carotid data acquisition), acquired
counts in the carotids, injected FDG dose, and
wholevesselTBRmax, as well as between the different
DG uptake parameters. All statistical analyses
ere performed using SPSS statistical package 16.0
SPSS Inc., Chicago, Illinois).
R E S U L T S
Population characteristics. A total of 82 patients
ere included in the study, of which all underwent
DG-PET/CT imaging. In 3 of the 82 patients,
DG-PET analysis could not be performed due to
igh FDG uptake in the thyroid, affecting the
isualization and analysis of FDG uptake within the
arotid arteries, leaving 79 eligible patients for
mage analysis. Patient characteristics are shown in
able 1.
FDG-PET imaging and CAD risk factors. Values for
wholevesselTBRmax, wholevesselSUVmax, SHS, and
PAS, as well as prevalence of different cutoff values
for wholevesselTBRmax, are shown in Table 1. Com-
parison of the 4 different FDG uptake parameters
showed highly significant positive correlations be-
tween all FDG uptake values (r 0.64; p 0.0001
for all comparisons).
Multivariate linear regression analysis with back-
ward elimination, showing the relation between
CAD risk factors and the various FDG-PET pa-
rameters, are shown in Table 2. BMI 30 kg/m2,
age 65 years, hypertension, smoking, and male
gender are shown to be strong determinants of the
FDG uptake in the carotid artery walls.
Furthermore, multivariate linear regression anal-
ysis showed that BMI 30 kg/m2, age 65 years,
hypertension, and smoking were independent risk
factors for carotid inflammation as depicted by
wholevesselTBRmax (Fig. 2). Further analysis revealed
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1199that the number of components of the metabolic
syndrome was significantly associated with
wholevesselTBRmax (Fig. 3). Independent predictors
or wholevesselSUVmax, SHS, and PAS values are
Table 1. Characteristics of the CAD Population
Characteristics n  82
Age, yrs 62.0 9.7
65 33 (40.2)
Gender
Male 67 (81.7)
Female 15 (18.3)
BMI, kg/m2 27.8 4.1
BMI 25 21 (25.6)
BMI 25 to 30 40 (48.8)
BMI 30 21 (25.6)
Lifestyle
Smoking
Never 37 (45.1)
Former 38 (46.3)
Current 7 (8.6)
Alcohol users 32 (39.0)
Exercisers 50 (61.0)
Medical history
Cardiovascular disease
Myocardial infarction 32 (39.0)
Percutaneous transluminal coronary
intervention
61 (74.4)
Coronary artery bypass surgery 23 (28.4)
Stroke/transient ischemic attack 3 (3.7)
Peripheral artery disease 4 (4.9)
Family history of cardiovascular disease 48 (58.5)
Hypertension 59 (72.0)
Duration of hypertension, months 133.9 119.4
Diabetes 31 (37.8)
Type I diabetes 3 (3.7)
Type II diabetes 28 (34.1)
Duration of diabetes, yrs 12.5 15.0
Fasting glucose, mmol/l 6.0 1.5
Medication
Statin 78 (95.1)
Duration, months 55.5 73.5
Beta-blocker 50 (61.0)
Calcium-channel blockers 13 (15.9)
ACE inhibitors 32 (39.0)
AT II blockers 10 (12.2)
Nitrates 9 (11.0)
Diuretics 13 (15.9)
Aspirin 75 (91.5)
Clopidrogrel 60 (73.2)
Insulin 6 (7.3)
Oral antidiabetics (metformin and/or others) 26 (31.7)
Continuedshown in Figure 4. iFDG-PET methodology. Concerning the intraob-
erver variability, intraclass correlation coefficient
alues for wholevesselTBRmax were 0.98 (0.94 to
0.99) for the left and 0.97 (0.90 to 0.99) for the
right carotid, indicating excellent agreement. The
mean time difference between first and second
reading was 29.1 days, with a range of 14 to 55
days.
No correlation was observed between wholevessel
TBRmax and FDG circulation time (r  0.20, p 
.08), acquired counts in the carotids (r  0.07,
 0.57), or injected FDG dose (r  0.15, p 
0.18).
D I S C U S S I O N
The aim of our study was to determine the preva-
lence of carotid vessel wall inflammation, quantified
by FDG-PET, in a CAD population and to iden-
tify which cardiovascular risk factors are related to
carotid inflammation. We demonstrate that low-
grade vessel wall inflammation is frequent in the
CAD population. In addition, we show that BMI
30 kg/m2, age65 years, history of hypertension,
moking, and male gender are important clinical
isk factors for carotid FDG uptake. Moreover,
DG uptake in the vessel wall showed a high
orrelation with the number of components of the
etabolic syndrome. These findings may be impor-
ant since histology studies have shown that plaque
Table 1. Continued
FDG-PET/CT n  79
Blood pool activity (left and right jugular
vein; SUVmean)
1.08 0.1
wholevesselTBRmax 2.0 0.3
wholevesselTBRmax 1.8 55 (69.6)
wholevesselTBRmax 2.0 32 (40.5)
wholevesselTBRmax 2.2 19 (24.1)
wholevesselTBRmax 2.4 10 (12.7)
wholevesselSUVmax 2.14 0.4
Single hottest segment 2.32 0.4
Percent active segments 56.3 37.7
0% 10 (12.7)
1%–30% 16 (20.2)
31%–60% 18 (22.8)
61%–90% 8 (10.2)
91%–100% 27 (34.2)
Values are mean  SD or n (%). Percent active segments is deﬁned as the
percentage of segments with TBRmax 1.9.
ACE  angiotensin-converting enzyme; AT II  angiotensin II; BMI  body
mass index; CAD  coronary artery disease; FDG-PET/CT  18F-
ﬂuorodeoxyglucose positron emission tomography/computed tomography;
SUVmax  maximum standardized uptake value; TBRmax  maximum target-
to-background ratio.nflammation is associated with plaque rupture and
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1200atherothrombotic events (19). Our results imply
that vessel wall inflammation may persist despite
medical therapy, even at the highest wholevesselT-
BRmax cutoff value.
Whether vessel wall inflammation measured by
FDG-PET is related to the occurrence of future
cardiovascular events is currently being investigated
in large longitudinal follow-up studies (20). The
determination of the prevalence of low-grade ca-
rotid inflammation depends on the choice of the
cutoff TBRmax value. It remains a matter of debate
s to whether the vessel wall is considered “in-
amed.” Histological studies of plaques obtained
fter carotid endarterectomy have shown that
ymptomatic plaques have higher macrophage con-
ent than asymptomatic plaques (21–23). Jander et
l. (22) revealed that the percentage of macrophage-
ich area of the plaque was 18  10% in recently
ymptomatic patients versus 11  4% in asymp-
omatic patients with carotid stenosis (p  0.005).
bviously, there is some overlap between these
roups, so pinpointing an exact number of macro-
hages to determine inflammation is difficult.
owever, it does provide an order of magnitude in
ar Regression Analyses With Backward Elimination to Identify
f Carotid Vessel Wall Inﬂammation
B 95% Conﬁdence Interval p Value
0.29 0.15 to 0.44 0.0001
0.16 0.04 to 0.28 0.01
0.18 0.04 to 0.33 0.01
0.27 0.04 to 0.51 0.02
0.14 0.02 to 0.30 0.09
0.38 0.22 to 0.55 0.0001
0.22 0.07 to 0.36 0.004
0.23 0.04 to 0.41 0.02
0.16 0.008 to 0.32 0.04
t
0.4 0.21 to 0.59 0.0001
0.2 0.03 to 0.36 0.018
0.32 0.012 to 0.62 0.042
0.18 0.000 to 0.36 0.05
ts
30.8 12.58 to 49.0 0.001
21.9 4.57 to 39.22 0.014
32.9 3.75 to 62.13 0.028
kground ratio (wholevesselTBRmax), whole-vessel maximum standardized uptake
gle hottest segment, and percent active segments were the response variables,
isease risk factors age 65 years, male gender, body mass index (BMI) 30
se, exercise, hypertension, diabetes, fasting glucose levels, and family history of
re the explanatory variables. Variables were retained in the model when p 
own. B is the regression coefﬁcient. Percent active segments is deﬁned as the
ith TBRmax 1.9.hich macrophage content is clinically relevant. Toranslate this into meaningful FDG-PET–related
utoff values poses another challenge. Tawakol et al.
7) performed in vivo FDG-PET imaging in 17
atients that subsequently underwent carotid end-
rterectomy. These authors showed that plaque
acrophage content was related to a gradual in-
rease in plaque FDG uptake. Most plaques with
BR values under 1.8 had macrophage areas in the
ange of 0% to 5%, lesions with TBRs between 1.8
nd 2.8 had 5% to 15% macrophages, and plaques
ith TBRs above 2.8 had macrophage areas 15%
7). For our study, in order to provide an estimate
bout the different degrees of FDG uptake in our
tudy population, we felt it reasonable to set TBR
ut points between 1.8 and 2.4 on the basis of the
forementioned pathologically derived values.
Clinical risk factors and vessel wall inﬂammation. We
observed that obesity, aging, history of hyperten-
sion, smoking, and male gender were independent
predictors of carotid inflammation as depicted by
FDG-PET. By far the strongest determinant for all
different FDG uptake parameters was increased
BMI. Furthermore, we found a significant relation
between the metabolic syndrome and vessel wall
inflammation. Our findings are in line with previ-
ous publications. In a retrospective study in patients
that underwent FDG-PET imaging for cancer
screening, Tahara et al. (12) showed that carotid
inflammation was associated with waist circumfer-
ence, hypertension, glucose intolerance, and the
metabolic syndrome. The similarities with our find-
ings are striking, considering the fact that very
different populations were investigated. We inves-
tigated a CAD population, whereas only 12.5% of
their population had a history of CAD. Moreover,
compared with our study, the number of men (68%
vs. 82%), BMI (24  3 kg/m2 vs. 28  4 kg/m2),
history of hypertension (42% vs. 72%), and the
number of diabetic patients (7% vs. 38%) were all
markedly lower. Furthermore, in contrast to the
current report, their study was performed on a
standalone PET scanner only, and they did not
apply a vascular-tailored imaging protocol. Despite
these differences, both studies revealed that obesity
and the number of components of the metabolic
syndrome were strong determinants of carotid in-
flammation (12). In a more recent prospective trial
in patients with known CAD or multiple cardio-
vascular risk factors, Rudd et al. (13) found carotid
FDG uptake to be significantly higher in patients
with known CAD and in males versus females.
Their results are in broad agreement, not only withTable 2. Multiple Line
Clinical Risk Factors o
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1201previous text, but also with the results of our study,
all indicating higher FDG uptake in the carotids of
men compared with women (12,13). This observa-
tion suggests that atherosclerotic plaques in men
may be more highly inflamed, perhaps providing a
pathological link for their higher rate of cardiovas-
cular events. However, the number of patients in
our study was twice that of the study by Rudd et al.
(13), providing greater statistical power. Further-
more, similar to the study population by Tahara et
al. (12), the number of men (73% vs. 82%), BMI
(26  5 kg/m2 vs. 28  4 kg/m2), history of
ypertension (61% vs. 72%), and the number of
Figure 2. Clinical Risk Factors of Carotid Vessel Wall Inﬂammati
This ﬁgure shows that body mass index (BMI) 30 kg/m2, age 65
carotid wall inﬂammation as depicted by the whole-vessel target-to
tions. p Values are adjusted for the other 4 predictors given in Tab
Figure 3. Relation Between the Metabolic Syndrome and Caroti
Whole-vessel TBRmax is whole-vessel maximum target-to-backgroun
ance was performed to test for between-group differences (p  0.02).mokers and ex-smokers (49% vs. 55%) were again
ll markedly lower in their study, whereas the
umber of diabetic subjects were similar to that of
ur study (37% vs. 38%). Additionally, as with the
tudy by Tahara et al. (12), the study population by
udd et al. (13) was more heterogeneous compared
ith that in the current trial, which only includes
atients with documented CAD.
The results of the present study have important
linical implications. Patients with the aforemen-
ioned characteristics might benefit most from anti-
nflammatory pharmacotherapy. A currently widely
vailable therapy known to exhibit anti-inflammatory
in CAD Patients
rs, hypertension, and smoking are independent predictors for
kground ratio (wholevesselTBRmax). Bars represent standard devia-
CAD  coronary artery disease.
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1202properties in addition to serum lipid lowering is
3-hydroxy-3-methyl-glutaryl-CoA reductase (st-
atins) (5). Novel anti-inflammatory drugs being
investigated as potential antiatherosclerotic thera-
pies are compounds such as inhibitors of
Factors of Carotid Vessel Wall Inﬂammation in CAD Patients
h CAD risk factors are independent predictors of carotid wall
ted by wholevesselSUVmax (A), single hottest segment (B), and per-
). Percent active segments is deﬁned as the percentage of seg-
.9. Bars represent standard deviations. p Values for
or the single hottest segment are adjusted for the other 3 predic-
he p value for the percent active segment is adjusted for the
reviations as in Figures 1 and 2.lipoprotein-associated phospholipase A2, anti-integrin and anticytokine therapies, and mycophe-
nolate mofetil, as well as vaccination with lipopro-
tein peptides (6,24). Furthermore, high-density
lipoprotein cholesterol (HDL) is known to have
anti-inflammatory properties, and drugs that in-
crease HDL by cholesteryl ester transfer protein
inhibition are currently being investigated in phase
II and phase III trials (25,26).
To assess the efficacy and safety of these novel
compounds, longitudinal follow-up studies assess-
ing clinical endpoints will need to be performed.
However, such studies are expensive and time
consuming, and expose many patients to a drug of
which the benefit or potential harm is unknown.
Therefore, prior to embarking on such studies,
efficacy can be investigated by use of surrogate
imaging markers (27). Imaging FDG uptake by the
vessel wall has emerged as a valuable surrogate
marker of vessel wall inflammation (28). The results
of our current study suggest that assessing the
efficacy of novel cardiovascular drugs with anti-
inflammatory properties might best be performed in
obese or metabolic syndrome patients.
The fact that obesity and the metabolic syndrome
show such a strong relation with FDG uptake in the
vessel wall is intriguing. The metabolic syndrome is
characterized by the clustering of obesity, insulin
resistance, dyslipidemia, and hypertension (29). A
meta-analysis in data from 172,573 patients showed
that the metabolic syndrome increases the risk for
atherothrombotic events and death, with a relative
risk of 1.78 (95% confidence interval: 1.58 to 2.00)
(30). Chronic low-grade inflammation, as reflected
by serum biomarkers, is known to accompany the
occurrence of obesity and the metabolic syndrome.
In fact, epidemiological studies have shown a clear
relation between obesity, metabolic syndrome, and
increased levels of inflammatory markers such as
tumor necrosis factor  (TNF-), interleukin 6
(IL-6), and CRP (31). A growing body of evidence
supports a common pathological mechanism link-
ing obesity to inflammation, insulin resistance, and
cardiovascular disease. Adipose tissue, in addition
to storing fat, is known to produce numerous
cytokines and hormones (31). Studies have shown
that adipocytes in obese subjects recruit macro-
phages, a process mediated by monocytes chemoat-
tractant protein-1 (MCP-1) (31). Activation of the
innate immune system occurs via toll-like receptors
and receptors for advanced glycation end products
that affect intracellular transcription pathways such
as the nuclear factor B (NF-B) and the c-JunFigure 4. Clinical Risk
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1203presence of inflammatory cells, adipocytes increase
their secretion of adipokines such as adiponectin
and TNF-, which are known to directly instigate
ndothelial dysfunction (31). TNF-, IL-6, and
adiponectin also cause insulin resistance that in-
duces oxidative stress and endothelial dysfunction
(32,33). Kim et al. (34) observed a positive corre-
lation between insulin resistance and adiponectin
levels but a negative correlation between the maxi-
mum TBR levels and adiponectin. This finding is
confirmed by 2 recently published studies (35,36),
which also found an inverse relationship between
adiponectin and arterial inflammation as assessed by
FDG uptake. Since adiponectin is known to act as
a brake on inflammation, and is therefore vascular
protective, in both healthy individuals and those
with vascular disease, it is intriguing that in those
with the highest levels of this hormone, there were
the lowest degrees of FDG arterial uptake (13,34–
37). In addition to the pro-atherogenic inflamma-
tory state, obesity is also associated with hyperten-
sion and increased very low–density lipoprotein
cholesterol, triglycerides, and decreased HDL cho-
lesterol (38), which might indirectly stimulate in-
vasion of the vessel wall by monocytes. Together,
these data indicate there is a direct pathophysiolog-
ical link between obesity, inflammation, and ath-
erosclerosis. Our data support the concept that
obesity and the metabolic syndrome are related to
vessel wall inflammation.
Of further interest is that we found a relation
between smoking and carotid inflammation. Simi-
lar to obesity, smoking has shown to induce a
proinflammatory state mediated by similar mech-
anisms as previously discussed, with elevated
levels of TNF-, IL-6, adiponectin and CRP,
insulin resistance, oxidative stress, and endothe-
lial dysfunction (33).
FDG-PET/CT methodology-related issues. In the pres-
nt study, image analyses were performed by 1
xperienced reader. This might reduce statistical
oise related to interobserver variation, but con-
erns might arise about intraobserver bias. How-
ver, the blinded and randomized intraobserver
greement measurements revealed very favorable
esults, indicating that image analyses by 1 reader
an be sufficient for the analysis being performed.
For all trials with FDG-PET imaging, concerns
ay arise about the impact of methodologically
elated variables, such as FDG circulation time,
njected FDG dose, and the acquired counts. Al-
hough minimized by the use of standardized im-ging protocols, such variations inevitably occur.
herefore, we investigated whether FDG circula-
ion time, injected FDG dose, and the acquired
ounts were associated with wholevesselTBRmax, and
observed that none of the methodologically related
variables significantly impacted the FDG uptake.
Therefore, it seems unlikely this could have intro-
duced bias in our study. Furthermore, as we did not
observe a clear difference in results between those
patients given high FDG doses and those given low
doses, our results suggest that lower FDG doses
could be used in future imaging studies.
Evaluation of cardiovascular risk factors for vessel
wall inflammation yielded quite consistent results
for wholevesselTBRmax, wholevesselSUVmax, SHS, and
AS values. Because of these consistent results
mong the FDG uptake parameters, we do not
elieve that the results of the present study have
een overly influenced by methodological issues
elated to the chosen way of image analysis. Fur-
hermore, our work might add to the current
iscussion regarding the most appropriate way of
ssessing vessel wall inflammation, including the
ros and cons of using the corrected TBR or the
ncorrected SUV FDG uptake values.
Study limitations. There are some limitations of our
study. First, we did not obtain serum lipid levels,
markers of glucose metabolism, or serum inflam-
matory markers. This would have provided more
complete information and more accurate determi-
nation of the metabolic syndrome. Second, this is a
cross-sectional study. Therefore, we could not ad-
dress whether there was a causal relationship be-
tween the presence of risk factors and vessel wall
inflammation. Third, we cannot provide more de-
tailed information about structural features of the
carotid walls (calcification, lipid core) because we
performed a non–contrast-enhanced CT as part of
the PET/CT in order to reduce radiation exposure
to patients. Furthermore, as we did not perform
magnetic resonance imaging to avoid additional
scanning time for the patients, morphological data
from a second imaging method are also not avail-
able. Future studies, focusing on new combined
imaging methods such as PET/magnetic resonance
imaging, should allow this. Finally, it is unknown
whether vessel wall inflammation measured by
FDG-PET/CT is predictive of future cardiovascu-
lar events. Longitudinal, prospective studies testing
this possibility are underway, although preliminary
retrospective reports are supportive of the hypoth-
esis (39,40).
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 4 , N O . 1 1 , 2 0 1 1
N O V E M B E R 2 0 1 1 : 1 1 9 5 – 2 0 5
Bucerius et al.
Carotid Vessel Wall Inflammation in CAD Patients
1204C O N C L U S I O N S
In the current study, we show that vessel wall
inflammation as quantified by FDG-PET/CT is
highly prevalent in the CAD population. Obesity,
age over 65 years, a history of hypertension, and
smoking seem to be important risk factors for
carotid inflammation. Clustering of components of
the metabolic syndrome also showed a strong rela-
tion with vessel wall inflammation. The results were
consistent across several FDG measured endpoints
that correlate with underlying inflammation. Fi-2708–11.
1
1
1
1
1
1
1
J Nucl Med 2006;4affect the results, suggesting that future studies
might use lower doses than previously, thereby
reducing the radiation exposure to each subject.
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